RebrAIn, a leader in precise targeting solutions for deep brain stimulation (DBS) and lesion techniques, announced the successful early completion of recruitment for the second phase of the groundbreaking PARKEO2 clinical trial. Sponsored by the Bordeaux University Hospital (CHU de Bordeaux) and funded by the French government, this study aims to revolutionise surgical treatment for Parkinson’s disease.
Related: Synchron reports positive results from Command study of its BCI system
The PARKEO2 trial, led by Professor Emmanuel Cuny of the CHU de Bordeaux, is a randomised, double-blind study comparing two surgical methods for DBS. It involves 128 patients across 11 renowned medical centre. With recruitment completed ahead of schedule, the study marks a significant step forward in expanding access to advanced Parkinson’s treatment.
The study’s leading recruitment centre include the “Assistance Publique – Hôpitaux de Marseille” (APHM), Nice University Hospital (CHU de Nice), and the “Hospices Civils de Lyon” (HCL), under the direction of esteemed professors Jean Régis, Denys Fontaine, and Emile Simon, respectively. Each institution has played a vital role in the trial’s success, reflecting France’s leadership in stereotactic and functional neurosurgery.
The trial is funded by a combination of public (National Clinical Research Hospital Program PHRC-N) and private funds, reflecting broad support and high expectations for its results. The multicenter nature of the study, involving several research centres across different regions, ensures a diverse and comprehensive approach to data collection and analysis. Furthermore, the inclusion of a control group allows for rigorous comparison and validation of the trial’s results.
RebrAIn’s involvement in the PARKEO2 trial includes its AI-powered neurosurgical planning software, designed to replicate optimal clinical outcomes in DBS treatments. This technology allows for faster, more precise, and safer surgeries by enabling personalized treatment plans based on individual patient data. Recently approved for a second indication by the FDA for VIM lesioning, RebrAIn’s solutions are set to redefine how neurosurgeons’ approach complex brain surgeries.
